Latest standards
Our new standards and reference materials are now available to order.
New Release: February 2026
Infectious Diseases
|
Product code
|
Product name
|
|
21/168
|
Oral Cholera Vaccine Inactivated
|
|
21/174
|
Vibrio cholerae O1 Ogawa LPS
|
|
21/178
|
Vibrio cholerae O1 Inaba LPS
|
|
24/124_NT
|
1st WHO International Standard for Antibodies to Sudan virus for neutralisation assays
|
|
18/222
|
Anti-Meningococcal Serotype p1.4 monoclonal antibody
|
|
16/322
|
2nd WHO International Standard Antiserum to Respiratory Syncytial Virus
|
Biotherapeutics
|
Product code
|
Product name
|
|
23/124
|
1st WHO International Standard for Ranibizumab
|
|
23/218
|
WHO International Reference Reagent Anti-A and Anti-B in IVIG: Positive Control
|
|
23/230
|
WHO International Reference Reagent Anti-A and Anti-B in IVIG: Negative Control
|
|
23/232
|
WHO International Reference Reagent Anti-A and Anti-B in IVIG: Limit reference preparation
|
Diagnostics
|
Product code
|
Product name
|
|
19/302
|
2nd WHO International Standard for Beta-2-Microglobulin (B2M)
|
Influenza
|
Product code
|
Product name
|
|
25/222
|
Influenza Antigen A/Switzerland/6849/2025 (IVR-278) (H1N1)
|
|
25/224
|
Influenza Anti-A/Missouri/11/2025-like (H1N1) HA serum
|
|
25/220
|
Influenza Antigen A/Singapore/GP20238/2024 (IVR-277) (H3N2)
|
|
25/226
|
Influenza Anti-A/Singapore/GP20238/2024-like (H3N2) HA serum
|
|
25/230
|
Influenza Virus Infectious A/Croatia/10136RV/2023 (H3N2)
|
|
25/232
|
Influenza Virus Infectious A/Singapore/GP20238/2024 (H3N2)
|
|
25/234
|
Influenza Virus Infectious A/Switzerland/6849/2025 (H1N1)
|
|
25/236
|
Influenza Virus Infectious A/Missouri/11/2025 (H1N1)
|
|
25/238
|
Influenza Virus Infectious IVR-277 A/Singapore/GP20238/2024 (H3N2)
|
|
25/240
|
Influenza Virus Infectious IVR-278 A/Switzerland/6849/2025 (H1N1)
|
|
25/242
|
Influenza Virus Infectious IVR-279 A/Missouri/11/2025 (H1N1)
|
|
25/244
|
Influenza Virus Infectious A/Valladolid/1187/2025 (H3N2)
|